2. Nymox Pivotal Phase 3 Fexapotide (NX-1207) BPH Extension Trial Successfully Meets Primary Endpoint

3. Primary Endpoint AUA BPH Symptom Score
Single injection results after median 42 months post-treatment (range 24 months to 65 months)
Mean improvement 5.3 points (p<.025 vs placebo)
First-line treatment with fexapotide mean improvement 7.16 points (p<.02 vs placebo)

4. BPH Improvement

5. AUA BPH Symptom Score Patient Responder Rate
Statistically significant higher proportion of long-term improved patients in AUA BPH Symptom Score (primary outcome variable) after a single injection in fexapotide treated subjects (64%) vs controls (p<.005)

6. Nocturia Median 42 months post-single injection treatment
Stabilization or improvement 87% (p<.03 vs placebo)

7. Surgery for BPH
1.7% in 2 years after 1-2 injections of fexapotide (p<.02 vs placebo)

8. Fexapotide Lowered Cancer Risk
Phase 2 US data showing reduced progression of low grade prostate cancer in fexapotide treated patients
This is in contrast to elevated cancer risk for some approved BPH oral medications

9. Nymox Fexapotide Advantages
Safe drug with durable efficacy
Office-based 1-2 minute injection
Single painless injection: no sedation, no anesthesia
No sexual side effects (commonly seen with older approved BPH medications)
No cardiovascular or hormonal side effects (commonly seen with older approved BPH medications)
Decreased cancer risk (Phase 2 data) (vs increased risk seen with older approved BPH medications)

10. Nymox Fexapotide Safety Profile
Superior to BPH approved medications
No sexual or cardiovascular side effects
No hormonal side effects
No increased risk of prostate cancer (decreased risk with fexapotide, Phase 2)

11. Nymox Fexapotide Efficacy Profile
Highly durable effect:
Single painless office injection with long-term benefit
After a single injection with fexapotide, the majority of patients in Phase 3 pivotal studies required no further oral medications or surgery for up to 5.4 years (median 42 months).
First-line single treatment after 3.5 years: 7.16 point mean improvement